Durham, NC (Vocus/PRWEB) April 07, 2011
AlphaMed Press announces the launch of a major peer-reviewed journal, STEM CELLS Translational Medicine (SCTM), answering an acknowledged need within the research and clinical communities for comprehensive coverage of stem cell science, stem cell-based regenerative medicine and tissue engineering, stem cell-based predictive toxicology, and cancer stem cell investigation.
STEM CELLS Translational Medicine will publish high-impact, peer-reviewed articles that will significantly advance the clinical utilization of stem cell molecular and cellular biology by bridging stem cell research and clinical trials. In addition to original manuscripts, case studies, and commentaries this unique journal will encourage researchers to submit data from their negative clinical trials for publication to rapidly share results that other researchers may find valuable.
The potential of stem cells therapies and regenerative medicine is both provocative and unique, offering the distinct possibility of eventually repairing or replacing tissues damaged from disease, including certain cancers. Under the leadership of the esteemed scientist-clinician Anthony Atala, MD as Editor, STEM CELLS Translational Medicine will speed expertly executed translations of emerging lab discoveries into noteworthy clinical trials.
“This exciting new journal will foster the proper growth and ethical development in this fast-moving field. There is a gap in the existing stem cells journal spectrum that STEM CELLS Translational Medicine will fill,” said Dr. Atala. “SCTM is the sister journal to STEM CELLS, the thirty-year-old premier journal in the field, and together they will elevate our science to applications that will impact the lives of many patients.”
The California Institute for Regenerative Medicine (CIRM) has provided a 3-year seed grant in support of the publication of SCTM.
“Science moves forward through publications in outstanding, peer-reviewed journals,” said Dr. Alan Trounson, CIRM President. “This new journal will provide a venue for studies that move stem cell research closer toward clinical trials. In addition to publishing new discoveries that help all scientists in their goals the journal will also take the unusual step of publishing studies considered “negative,” with results that did not back up the original hypothesis or that did not show a new path to therapies, which will save other scientists the time of carrying out those experiments.”
In addition, the journal will launch a multi-media platform, allowing for the production of series of online podcasts that focus on methods or clinical processes and feature key opinion leaders and thought-provoking roundtables to highlight important issues or feature premier stem cells institutes and laboratories.
SCTM will be available in December 2011.
- Miracle chemical ‘cocktail’ could cure spinal cord damage
- Combined expression of pro-regenerative transcription factors and transplanted stem cells to promote corticospinal tract regeneration.
- Structural and Functional Substitution of Deleted Primary Sensory Neurons by New Growth from Intrinsic Spinal Cord Nerve Cells: An Alternative Concept in Reconstruction of Spinal Cord Circuits
- U2FP SCI CureCast now includes the 8th episode!
- Chronic SCI: ReNetX Bio Launched to Advance Innovative Neuro-Regenerative Technology Developed at Yale University
- Overexpression of KLF6 in corticospinal tract neurons promotes axon growth after spinal injury
- A potent anti-spastic effect after intrathecal NK1 antisense oligonucleotide or subpial AAV9-NK1-ShRNA delivery in rats with chronic spinal transection-induced muscle spasticity
- Non-Invasive Paired Stimulation and Anklebot Robot to Improve Lower Extremity Motor Recovery in Chronic Spinal Cord Injury
- Spinal cord injury: Using cortical targets to improve motor function
- 43 Disability Protesters outside of Senate Mitch McConnell’s office arrested over proposed severe Medicaid cuts.
- Interaction of reactive astrocytes with type I collagen induces astrocytic scar formation through the integrin–N-cadherin pathway after SCI
- SCI Stem-cell pioneer enters the political field in California
- Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias’ AST-OPC1
- Induction of immune tolerance by short-course immunosuppresion after spinal grafting of allogeneic neural precursors in pigs with previous chronic spinal cord traumatic injury.
- Growth Hormone Improves Sensory Function in Complete Spinal Injury
Follow on TwitterMy Tweets